Bone Biologics Crescita futura

Future criteri di controllo 0/6

Bone Biologics is forecast to grow earnings at 4.9% per annum. EPS is expected to grow by 53.7% per annum.

Informazioni chiave

4.9%

Tasso di crescita degli utili

53.7%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	27.1%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	12 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Jun 07

Bone Biologics prices $5.1M underwritten public offering

Oct 07

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Mar 18

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:BBLG - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-5	N/A	N/A	1
12/31/2025	N/A	-4	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
6/30/2024	N/A	-5	-7	-7	N/A
3/31/2024	N/A	-6	-10	-10	N/A
12/31/2023	N/A	-9	-10	-10	N/A
9/30/2023	N/A	-7	-9	-9	N/A
6/30/2023	N/A	-6	-7	-7	N/A
3/31/2023	N/A	-5	-4	-4	N/A
12/31/2022	N/A	-1	-4	-4	N/A
9/30/2022	N/A	-3	-2	-2	N/A
6/30/2022	N/A	-2	-2	-2	N/A
3/31/2022	N/A	-2	-2	-2	N/A
12/31/2021	N/A	-2	-1	-1	N/A
9/30/2021	N/A	-2	-1	-1	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-2	0	0	N/A
12/31/2020	N/A	-2	0	0	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	-1	-1	N/A
3/31/2020	N/A	-3	-2	-2	N/A
12/31/2019	N/A	-3	-3	-3	N/A
9/30/2019	N/A	-4	-4	-4	N/A
6/30/2019	N/A	-4	-5	-5	N/A
3/31/2019	N/A	-4	-4	-4	N/A
12/31/2018	N/A	-4	-4	-4	N/A
9/30/2018	N/A	-6	-4	-4	N/A
6/30/2018	N/A	-8	-3	-3	N/A
3/31/2018	N/A	-6	N/A	-3	N/A
12/31/2017	N/A	-7	N/A	-3	N/A
9/30/2017	N/A	-14	N/A	-4	N/A
6/30/2017	N/A	-16	N/A	-5	N/A
3/31/2017	N/A	-22	N/A	-6	N/A
12/31/2016	N/A	-26	N/A	-7	N/A
9/30/2016	N/A	-24	N/A	-7	N/A
6/30/2016	N/A	-23	N/A	-7	N/A
3/31/2016	N/A	-19	N/A	-6	N/A
12/31/2015	N/A	-14	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-4	N/A
6/30/2015	N/A	-6	N/A	-4	N/A
3/31/2015	N/A	-6	N/A	-3	N/A
12/31/2014	N/A	-4	N/A	-3	N/A
9/30/2014	N/A	-4	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	0	N/A
3/31/2014	N/A	-1	N/A	0	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: BBLG is forecast to remain unprofitable over the next 3 years.

Guadagni vs Mercato: BBLG is forecast to remain unprofitable over the next 3 years.

Guadagni ad alta crescita: BBLG is forecast to remain unprofitable over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if BBLG's revenue is forecast to grow faster than the US market.

Ricavi ad alta crescita: BBLG is forecast to have no revenue next year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if BBLG's Return on Equity is forecast to be high in 3 years time

Bone Biologics Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased to US$4.88

Price target decreased to US$4.88

Recent updates

Bone Biologics Corporation Appoints Phillip Meikle to Board of Directors

Bone Biologics Corporation Announces Resignation of Don Hankey as Director, Effective Immediately

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million.

Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024

New major risk - Share price stability

Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million.

Bone Biologics Corporation has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Bone Biologics Corporation has filed a Follow-on Equity Offering.

Bone Biologics Corporation Announces Board Changes

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation Receives Non-Compliance Notice From Nasdaq

New major risk - Financial position

Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023

New major risk - Share price stability

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Nasdaq Notifies Bone Biologics Regarding Non-Compliance with the Minimum Bid Price Requirement

Bone Biologics Corporation Resigns Stephen Laneve as Director

Bone Biologics Receives Written Notice from the NASDAQ Regarding Minimum Bid Price Requirement

Price target decreased to US$4.88

Price target decreased to US$4.88

Bone Biologics Corporation has completed a Composite Units Offering.

Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million.

Bone Biologics prices $5.1M underwritten public offering

Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Less than half of directors are independent

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita